<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Enfuvirtide</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00109</strong>&#160; (BIOD00106, BTD00106)</td></tr><tr><th>Type</th><td>biotech</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>36 residue synthetic peptide that inhibits <span class="caps">HIV</span>-1 fusion with CD4 cells. N-terminal acetylated, C-terminal amide.</p></td></tr><tr><th>Protein structure</th><td><img alt="No structure small" src="/assets/no_structure_small-e8790a148b09ecc5ad9f5b4926a538e7.png"></td></tr><tr><th>Protein chemical formula</th><td>C<sub>204</sub>H<sub>301</sub>N<sub>51</sub>O<sub>64</sub></td></tr><tr><th>Protein average weight</th><td>4491.8760</td></tr><tr><th>Sequences</th><td><pre class="sequence">&gt;DB00109 sequence
YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF</pre><small><a class="btn btn-info btn-sm" href="/drugs/DB00109/polypeptide_sequences.fasta">Download FASTA Format</a></small></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Envelope polyprotein GP160 precursor [Contains: Exterior membrane glycoprotein,GP120, Transmembrane glycoprotein,GP41]</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Fuzeon</td><td>Roche Pharmaceuticals</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/hiv-fusion-inhibitors">HIV Fusion Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>159519-65-0</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Peptides</td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS.</td></tr><tr><th>Pharmacodynamics</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Mechanism of action</th><td>Enfuvirtide binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected. Enfuvirtide is a biomimetic peptide that was rationally designed to mimic components of the HIV-1 fusion machinery and displace them, preventing normal fusion. 

</td></tr><tr><th>Absorption</th><td>After a 90 mg single subcutaneous injection of Enfuvirtide into the abdomen in 12 HIV-1 infected subjects, the mean peak concentration is 4.59+/-1.5 ug/ml and the median time to peak concentration was 8 hours (ranged from 3 to12 hours).</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>5.5 &#177; 1.1 L</li>
</ul></td></tr><tr><th>Protein binding</th><td>92%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Expected to undergo catabolism to its constituent amino acids, with subsequent recycling of the amino acids in the body pool.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>3.8 +/- 0.6 hrs</td></tr><tr><th>Clearance</th><td><ul>
	<li>24.8 +/- 4.1 mL/h/kg [<span class="caps">HIV</span>-1 infected adult and pediatric subjects following a 90-mg single SC dose of enfuvirtide]</li>
	<li>30.6 +/- 10.6 mL/h/kg [Following 90-mg twice daily dosing of <span class="caps">FUZEON</span> SC in combination with other antiretroviral agents in <span class="caps">HIV</span>-1 infected subjects]</li>
	<li>40 +/- 17 mL/h/kg [pediatric patients in the presence of concomitant medications including antiretroviral agents receiving the 2 mg/kg twice daily dose]</li>
</ul></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Human Immunodeficiency Virus</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Hoffmann la roche inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.roche.com">F Hoffmann La Roche Ltd.</a></li>
<li><a href="http://www.roche.com">F Hoffmann-La Roche Ltd.</a></li>
<li><a href="http://www.gilead.com">Gilead Sciences Inc.</a></li>
<li><a href="http://www.pharmaciaupjohn.com">Pharmacia Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Powder, for solution</td><td>Subcutaneous</td><td></td></tr></tbody></table></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>